articleThe LancetJan 1, 2007Closed access

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

ISIan SmithMPMarion ProcterRDRichard D. GelberSGSébastien GuillaumeAFA. Feyereislova

Institute of Cancer Research · Royal Marsden Hospital · +26 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,511
total citations
FWCI
77.45
Percentile
100%
References
22
Citations per year

Authors

24

Topics & keywords

Topics
Keywords
  • Trastuzumab
  • Medicine
  • Internal medicine
  • Hazard ratio
  • Breast cancer
  • Oncology
  • Clinical endpoint
  • Clinical trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.